Effectiveness and Safety of Treatment with Nucleo(s)tide Analogues in Patients with Hepatitis B-related Cirrhosis

Author:

Gerdzhikova Klimentina,Donkov Ivo,Komitova Teodora,Genov Jordan,Vladimirov Borislav,Mitova Rumyana,Chetirska Milena,Asenova Boryana,Bedran Ali,Pavlov Kaloyan

Abstract

Data from Bulgaria are limited on the long-term effects of nucleo(s)tide analogues (NAs) to patients with hepatitis B-related cirrhosis. The study aimed to evaluate the overall efficacy and renal safety of NAs in such cohort of patients, comparing treated with high to low-barrier NAs. We retrospectively analyzed 58 patients with HBV cirrhosis (74.1% in compensated stage) for a period of 5 years. Thirty-five patients received NAs with high-barrier of resistance: Tenofovir disoproxil fumarate and Entecavir (followed up for 51.63 ± 30.3) and 23 received NAs with low-barrier of resistance: Lamivudine and Telbivudine (followed up for 56.7 ± 48.4). After a median treatment time of 53.7 months virological response (VR) rates (HBV DNA<10 IU/ml) were 91.4% in high barrier and 87.0% in low barrier NAs groups. Undetectability of HBVDNA was influenced most by the treatments’ duration. Serological response reached 57.1%, similar for the two treatment groups. One patient (1.7%) cleared HBsAg and discontinued NAs (TDF). Multidrug resistance (MDR) occurred in 15.5% of LAM recipients only. One-, 3-, 5-, 8- year MDR rates were 0.0%; 11.1%; 33.3% and 77.6%. A slight improvement of the renal function was observed in 85.7% and 69.6% of the patients treated with high and low-barrier NAs. Dose reduction for renal toxicity was required in 1.7%. Decompensated cirrhosis and T2DM were the main risk factors for renal function decline. Long-term therapy with high and low barrier NAs was equally effective and renally safe in patients with HBV-related cirrhosis.

Publisher

Prof. Marin Drinov Publishing House of BAS (Bulgarian Academy of Sciences)

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3